share_log

We Like The Quality Of Medtronic's (NYSE:MDT) Earnings

We Like The Quality Of Medtronic's (NYSE:MDT) Earnings

我們喜歡美敦力(紐交所:MDT)收益的質量
Simply Wall St ·  2024/12/06 19:06

Medtronic plc's (NYSE:MDT) solid earnings announcement recently didn't do much to the stock price. We did some digging, and we think that investors are missing some encouraging factors in the underlying numbers.

美敦力集團(紐約證券交易所代碼:MDT)最近公佈的穩健收益對股價沒有多大影響。我們進行了一些挖掘,我們認爲投資者在基礎數據中遺漏了一些令人鼓舞的因素。

big
NYSE:MDT Earnings and Revenue History December 6th 2024
紐約證券交易所:MDT 收益和收入歷史記錄 2024 年 12 月 6 日

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

To properly understand Medtronic's profit results, we need to consider the US$996m expense attributed to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And, after all, that's exactly what the accounting terminology implies. Assuming those unusual expenses don't come up again, we'd therefore expect Medtronic to produce a higher profit next year, all else being equal.

爲了正確了解美敦力的利潤業績,我們需要考慮歸因於不尋常項目的9.96億美元支出。看到不尋常的項目使公司利潤損失從來都不是一件好事,但從好的方面來看,情況可能遲早會好轉。我們調查了數千家上市公司,發現不尋常的物品本質上往往是一次性的。而且,畢竟,這正是會計術語的含義。假設這些不尋常的支出不會再次出現,因此,在其他條件相同的情況下,我們預計美敦力明年將實現更高的利潤。

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

這可能會讓你想知道分析師對未來盈利能力的預測。幸運的是,您可以點擊此處查看根據他們的估計描繪未來盈利能力的交互式圖表。

Our Take On Medtronic's Profit Performance

我們對美敦力利潤表現的看法

Because unusual items detracted from Medtronic's earnings over the last year, you could argue that we can expect an improved result in the current quarter. Because of this, we think Medtronic's earnings potential is at least as good as it seems, and maybe even better! And the EPS is up 6.7% over the last twelve months. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. You'd be interested to know, that we found 1 warning sign for Medtronic and you'll want to know about it.

由於不尋常的項目削弱了美敦力去年的收益,你可能會爭辯說,我們可以預期本季度的業績會有所改善。因此,我們認爲美敦力的盈利潛力至少和看起來一樣好,甚至可能更好!在過去的十二個月中,每股收益增長了6.7%。本文的目標是評估我們在多大程度上可以依靠法定收益來反映公司的潛力,但還有很多需要考慮的地方。有鑑於此,如果你想對公司進行更多分析,了解所涉及的風險至關重要。你可能會有興趣知道,我們找到了美敦力的 1 個警告標誌,你會想知道的。

This note has only looked at a single factor that sheds light on the nature of Medtronic's profit. But there are plenty of other ways to inform your opinion of a company. Some people consider a high return on equity to be a good sign of a quality business. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

這份報告只研究了揭示美敦力利潤性質的單一因素。但是,還有很多其他方法可以讓你對公司的看法。有些人認爲高股本回報率是優質業務的好兆頭。因此,你可能希望看到這份擁有高股本回報率的公司的免費集合,或者這份內部所有權高的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?擔心內容嗎?直接聯繫我們。或者,發送電子郵件給編輯組(網址爲)simplywallst.com。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論